Evidence profile
Tirzepatide
Tirzepatide study rows link each listed finding to its source, model or population, and endpoint.
Cited headline finding
The trial reported a −20.9% mean body-weight change in one study arm. ↗
2,539 adults with obesity, or overweight plus a complication, excluding diabetesJastreboff et al., NEJM 2022Phase 3
Mechanism scope
How cited research characterizes Tirzepatide
Coskun et al. characterized a fatty-acid-modified dual GIP/GLP-1 agonist in receptor assays, mouse experiments, and Phase 1 work.
Open question
What the cited Tirzepatide sources do not resolve
The cited Tirzepatide trial reports its body-weight endpoint for the stated population; the source does not establish that finding outside that trial context.
Sources: Jastreboff et al., NEJM 2022 ↗
| Finding | Year | n | Model or population | Endpoint | Source | Evidence tier |
|---|---|---|---|---|---|---|
| The trial reported a −20.9% mean body-weight change in one study arm. | 2022 | 2,539 | 2,539 adults with obesity, or overweight plus a complication, excluding diabetes | Coprimary body-weight change; treatment-regimen estimand | Jastreboff et al., NEJM 2022 ↗ | Phase 3 |
| The study characterized a fatty-acid-modified dual GIP/GLP-1 agonist in experimental systems and Phase 1 work. | 2018 | Not stated | Receptor assays, mouse experiments, and Phase 1 human work | Receptor signalling and pharmacology | Coskun et al., Molecular Metabolism 2018 ↗ | Phase 1–2 |
Reviewer: Ember Peptides source-verification editorial review · Review date: 2026-09-13